Next, to evaluate the predictive value of the supercluster signatures for therapy response, we analyzed a dataset comprising pre-treatment tumor samples from eight patients with EGFR-mutant lung cancer treated with the tyrosine kinase inhibitor Osimertinib[38]. This evidence concerns the gene EGFR and lung cancer.